Lupin lost 0.63% to Rs 914 at 15:25 IST on BSE, with the stock sliding on profit booking after 5-day 5.77% gains.
Meanwhile, the S&P BSE Sensex was up 20.94 points or 0.1% at 21,100.66.
On BSE, so far 51,000 shares were traded in the counter as against average daily volume of 89,297 shares in the past one quarter.
The stock hit a high of Rs 924 and a low of Rs 908.75 so far during the day. The stock had hit a 52-week low of Rs 569 on 1 March 2013. The stock had hit a record high of Rs 946.35 on 11 October 2013.
The stock had outperformed the market over the past one month till 20 December 2013, surging 7.11% compared with the Sensex's 2.15% rise. The scrip had also outperformed the market in past one quarter, advancing 6.05% as against Sensex's 4.03% rise.
The large-cap company has equity capital of Rs 89.64 crore. Face value per share is Rs 2.
More From This Section
Shares of Lupin had gained 5.77% in five trading sessions to settle at Rs 920.05 on Friday, 20 December 2013, from a recent low of Rs 869.80 on 13 December 2013.
Lupin's consolidated net profit surged 39.8% to Rs 406.18 crore on 17.5% growth in net sales to Rs 2631.46 crore in Q2 September 2013 over Q2 September 2012.
Lupin is a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and cephalosporin segment.
Powered by Capital Market - Live News